Get the Stockscreener App
19.53
4.89%
0.91
After Hours:
19.53
Arrivent Biopharma Inc stock is traded at $19.53, with a volume of 274.75K.
It is up +4.89% in the last 24 hours and down -9.67% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$18.62
Open:
$18.74
24h Volume:
274.75K
Relative Volume:
0.77
Market Cap:
$668.17M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-7.4451
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
+8.56%
1M Performance:
-9.67%
6M Performance:
-26.58%
1Y Performance:
-18.15%
1-Day Range:
$18.47
$19.86
1-Week Range:
$16.10
$19.86
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
19.53 | 755.39M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Custom strategy builders for tracking ArriVent BioPharma Inc.Weekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - Newser
Candlestick signals on ArriVent BioPharma Inc. stock todayForecast Cut & Technical Pattern Recognition Alerts - Newser
How to interpret RSI for ArriVent BioPharma Inc. stockMarket Activity Summary & Free High Return Stock Watch Alerts - Newser
What machine learning models say about ArriVent BioPharma Inc.Market Performance Summary & Fast Entry Momentum Alerts - Newser
Does ArriVent BioPharma Inc. fit your quant trading modelWeekly Market Outlook & Safe Entry Trade Signal Reports - Newser
ArriVent BioPharma Posts Q2 Loss as Cancer Drug Pipeline Advances Toward Key Milestones - MSN
Will ArriVent BioPharma Inc. outperform the marketWeekly Profit Report & Verified Swing Trading Watchlist - Newser
News impact scoring models applied to ArriVent BioPharma Inc.Weekly Profit Analysis & Long-Term Safe Investment Plans - Newser
Will ArriVent BioPharma Inc. price bounce be sustainableMarket Activity Report & Long-Term Safe Investment Plans - Newser
Comparing ArriVent BioPharma Inc. in custom built stock radars2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Advanced analytics toolkit walkthrough for ArriVent BioPharma Inc.Product Launch & Safe Entry Trade Signal Reports - Newser
Trend analysis for ArriVent BioPharma Inc. this weekMarket Activity Report & Daily Profit Focused Screening - Newser
ArriVent BioPharma Inc. recovery potential after sell offEarnings Recap Summary & Risk Managed Investment Entry Signals - Newser
Can trapped investors hope for a rebound in ArriVent BioPharma Inc.Gap Down & Weekly Setup with High ROI Potential - Newser
ArriVent BioPharma Inc. Stock Lags Behind Sector Benchmarks2025 Price Momentum & Fast Moving Trade Plans - beatles.ru
ArriVent BioPharma Inc. Recovery Hinges on Volume Breakout2025 Biggest Moves & Weekly High Return Forecasts - metal.it
Omega Advisors' Q2 Holdings: New Buys, Exits, and Stakes Increased - AInvest
ArriVent BioPharma Inc. Price Targets Raised After ReboundMarket Trend Review & Real-Time Sentiment Analysis - mustnews.co.kr
ArriVent Biopharma price target lowered to $33 from $40 at Citi - MSN
Is ArriVent BioPharma Inc. trending in predictive chart models2025 Price Targets & Community Consensus Picks - Newser
ArriVent BioPharma Advances Cancer Therapeutics Pipeline - MSN
Mineralys: HC Wainwright Raises PT to $42, Maintains Buy Rating - AInvest
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
ArriVent BioPharma Inc. stock retracement – recovery analysisM&A Rumor & Real-Time Volume Trigger Notifications - Newser
ArriVent Biopharma price target raised to $42 from $40 at H.C. Wainwright - TipRanks
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $33 to $45 - 富途牛牛
H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential - Investing.com Canada
ArriVent BioPharma Inc. stock trend outlook and recovery pathFree Short Term High Yield Stock Tips - Newser
What makes ArriVent BioPharma Inc. stock price move sharplyFree Real Time Alerts Based on AI Prediction - Newser
ArriVent Biopharma sees cash runway into mid-2027 - TipRanks
Why ArriVent BioPharma Inc. stock attracts strong analyst attentionFree Low Capital High Return Stock Plans - Newser
ArriVent Biopharma reports Q2 EPS (90c), consensus (71c) - TipRanks
Does ArriVent BioPharma Inc. qualify in momentum factor screeningSector Rotation Strategy for Smart Traders - Newser
Understanding ArriVent BioPharma Inc.’s price movementFree Breakout Entry Signal Confirmation Tool - Newser
ArriVent BioPharma Reports Q2 GAAP EPS of -$0.90, Misses Expectations - AInvest
ArriVent BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ArriVent Posts Wider Loss in Fiscal Q2 - The Motley Fool
ArriVent Posts Wider Loss in Fiscal Q2 - The Globe and Mail
ArriVent BioPharma, Inc. SEC 10-Q Report - TradingView
ArriVent's Lung Cancer Drug Shows Promise in Phase 1b Trial, Reports $335M Cash Position - Stock Titan
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Wednesday - Defense World
Predicting ArriVent BioPharma Inc. trend using moving averagesFree Consistent Profit Pattern Recognition Tools - Newser
How hedge fund analytics apply to ArriVent BioPharma Inc. stockEntry Confirmation Using Short-Term Forecasting - Newser
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):